Skip to main content
. 2011;13(1):20–33.

Table 5.

Randomized, Placebo-Controlled Trials of PDE5 Inhibitors for the Treatment of Clinical BPH

Treatment Effect
Reference Drug Dose (mg) No. † IPSS † Qmax
McVary KT et al26 Sildenafil 100 189 6.3 0.31
McVary KT et al27 Tadalafil 5 281 2.8 0.5
20 281 3.8 0.5
Stief CG et al28 Vardenafil 10 bid 222 5.9 1.6
Roehrborn CG et al29 Tadalafil 5 212 4.87 1.64

BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; PDE5, phosphodiesterase type 5.